BOT price action, page-183

Let's not all get ahead of our selves. Yes we know it is all huge but how huge? No one knows do they.

Now can I share with you a priapismic posting, a quote a few months ago however I do not know who is attributed to it due to the shody journalism in prose. It's a choice of two but the comparison is laughable and whilst any publicity is good publicity, this talk is pure baloney.

"I think it's going to be really significant. It's the only time in my career we've had a drug that cures a lot of diseases and it doesn't seem to cause side effects."

Botanix is holding clinical trials on a CBD gel to treat acne and dermatitis, and Mr Callahan says early results are promising.

Medlab Clinical meanwhile is investigating using a mix of CBD and THC - the compound that gives cannabis users their high - via a cheek spray to treat pain in cancer patients.

"We've got clinical trials going on at Sydney Royal North Shore Hospital that are progressing nicely; the data from them is sensational," says chief executive Sean Hall.

"We're looking down the face of a potentially another Lipitor."

That's a bold claim, given that the cholesterol-lowering drug made Pfizer as much as $A18 billion a year during the 2000s.

So we await and in the interim amuse ourselves with gentle banter throwing up all sorts of curve balls and distractions. What does impress me is the professionalism of our Board albeit they seem to be very quiet. Permetrex by itself may pay for a round of coffees but the big 3 results await.